<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stone, Gregg</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Hyporesponsiveness to Clopidogrel Does Not Predict 1-Year Mortality</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">An analysis from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents [ADAPT-DES; NCT00638794] trial showed that hyporesponsiveness to clopidogrel was not independently predictive of mortality at 1-year after percutaneous coronary intervention with a drug-eluting stent. Although hyporesponsiveness to clopidogrel was associated with increased risk of stent thrombosis and myocardial infarction, it was also associated with a reduced risk of major bleeding, which has been strongly related to mortality.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>